05 · Access & Industry
A 2026 national survey found that 11% of adults reported currently using a GLP-1 medicine for weight loss
Usage has jumped, but cost, coverage, trust, and medical fit still keep many people outside the category.
A 2026 national survey found that 11% of adults reported currently using a GLP-1 medicine for weight loss. The figure described a rapid change in consumer exposure, but it also showed that most adults were not using these medicines.
The access bottleneck was not simply awareness. Price and insurance coverage separated a highly visible category of medicines from the households that could sustain a prescription, leaving uptake uneven even as supply conditions improved.
The number is self-reported survey evidence, not proof of effectiveness or a cause of population health trends. It cannot show what any individual should use or whether reported use will persist.
DisclaimerEducational news and research awareness content. Not medical advice.Read full disclaimer ▾
This page shares third-party news coverage, official research listings, and public clinical updates for educational awareness only. Catalyst does not present this information as medical advice, treatment guidance, or a claim of safety, efficacy, or approval.
Related context
How this story connects across the peptide landscape.
Continue reading · Access & IndustryPeptide News / Access & IndustryEmployer coverage is still the access question behind obesity medicinesCNBC Health and Science · Jul 8, 2026 · scroll to read